Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Calidi Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Calidi Biotherapeutics, Inc.

CLDI CLDI-WT CLDWW

Calidi Biotherapeutics, Inc.

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing proprietary allogeneic stem cell and enveloped virus platforms to deliver oncolytic viruses for cancer treatment. Its product candidates aim to enhance viral delivery, protect against immune neutralization, and modify tumor microenvironments. Focused on solid tumors and brain cancers, Calidi leverages off-the-shelf cell therapies to improve efficacy and safety in cancer immunotherapy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Calidi Biotherapeutics, Inc.

1
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports $4.1 Million Net Loss in Q1 2026, Focuses on RedTail Platform

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports $20.1 Million Net Loss for 2025, Decrease from Previous Year

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports $5.2 Million Net Loss in Q3 2025, Seeks Additional Funding

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports $5.8 Million Net Loss for Q2 2025, Faces Liquidity Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports Improved Net Loss and Increased Assets for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports $22.2 Million Net Loss for 2024, Decreased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Calidi Biotherapeutics, Inc. Calidi Biotherapeutics Reports Significant Financial Decline, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments